Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn's disease patients with prior failure to anti-TNF treatment

DSpace/Manakin Repository

Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn's disease patients with prior failure to anti-TNF treatment
 
Biemans, Vince B C; van der Woude, C Janneke; Dijkstra, Gerard; van der Meulen-de Jong, Andrea E; Löwenberg, Mark; de Boer, Nanne K; Oldenburg, Bas; Srivastava, Nidhi; Jansen, Jeroen M; Bodelier, Alexander G L; West, Rachel L; de Vries, Annemarie C; Haans, Jeoffrey J L; de Jong, Dirk; Hoentjen, Frank; Pierik, Marieke J; Dutch Initiative on Crohn and Colitis (ICC)
(2020) Alimentary Pharmacology & Therapeutics, volume 52, issue 1, pp. 123 - 134
(Article)
Abstract
BACKGROUND: Both vedolizumab and ustekinumab can be considered for the treatment of Crohn's disease (CD) when anti-TNF treatment fails. However, head-to-head trials are currently not available or planned. AIM: To compare vedolizumab and ustekinumab in Crohn´s disease patients in a prospective registry specifically developed for comparative studies with correction for ... read more
Download/Full Text
Open Access version via Utrecht University Repository Publisher version
Version on publisher website for UU-students and staff
Version on publisher website
 
Keywords: Gastroenterology, Pharmacology (medical), Hepatology, Journal Article
DOI: https://doi.org/10.1111/apt.15745
ISSN: 0269-2813
Publisher: Wiley-Blackwell
Note: Funding Information: V.B.C. Biemans has no conflicts of interest to declare. C.J. van der Woude has served on advisory boards and/or received financial compensation from the following companies: MSD, FALK Benelux, Abbott laboratories, Mundipharma Pharmaceuticals, Janssen, Takeda, and Ferring during the last 3 years. A.E. van der Meulen‐de Jong has served on advisory boards, or as speaker or consultant for Takeda, Tramedico, AbbVie, and has received grants from Takeda. G. Dijkstra unrestricted research grants from Abbvie, Takeda and Ferring Pharmaceuticals. Advisory boards for Mundipharma and Pharmacosmos. Received speakers fees from Takeda and Janssen Pharmaceuticals. M. Löwenberg has served as speaker and/or principal investigator for: Abbvie, Celgene, Covidien, Dr. Falk, Ferring Pharmaceuticals, Gilead, GlaxoSmithKline, Janssen‐Cilag, Merck Sharp & Dohme, Pfizer, Protagonist therapeutics, Receptos, Takeda, Tillotts, Tramedico. He has received research grants from AbbVie, Merck Sharp & Dohme, Achmea healthcare and ZonMW. N.K.H. de Boer has served as a speaker for AbbVie, Takeda and MSD. He has served as consultant and principal investigator for Takeda and TEVA Pharma B.V. He has received (unrestricted) research grants from Dr. Falk and Takeda. B. Oldenburg speaker: Ferring, MSD, Abbvie. Advisory boards: Ferring, MSD, Abbvie, Takeda, Pfizer, Janssen. Research Grants: Abbvie, Ferring, Takeda, Pfizer, MSD, dr. Falk. N. Srivastava has no conflict of interest to declare. J.M. Jansen has served on advisory boards, or as speaker or consultant for Abbvie, Amgen, Ferring, Fresenius, Janssen, MSD, Pfizer, Takeda. A.G.L. Bodelier has served as speaker and/ or participant in advisory board for: Abbvie, Merck Sharp & Dohme, Takeda, Vifor Pharma, Mundipharma. R.L. West has participated in advisory board and/or received financial compensation from the following companies: Jansen and Abbvie. A.C. de Vries has participated in advisory board and/or received financial compensation from the following companies: Jansen, Takeda, Abbvie and Tramedico. D.J. de Jong Received consulting fees from Synthon, Pharma, Abbvie, and MSD, and travel fees from Falk Pharma, Takeda, Abbvie, MSD, Ferring, Vifor Pharma, and Cablon Medical. J.J.L. Haans reports personal fees from advisory board for Takeda Nederland B.V., personal fees from advisory board for Lamepro B.V., outside the submitted work. F. Hoentjen has served on advisory boards, or as speaker or consultant for Abbvie, Celgene, Janssen‐Cilag, MSD, Takeda, Celltrion, Teva, Sandoz and Dr Falk , and has received unrestricted grants from Dr Falk, Janssen‐Cilag, Abbvie. M.J. Pierik has served on advisory boards, or as speaker or consultant for Abbvie, Janssen‐Cilag, MSD, Takeda, Ferring, Dr Falk, and Sandoz and has received unrestricted grants from, Janssen‐Cilag, Abbvie and Takeda outside the submitted work. Declaration of personal interests: Funding Information: No funding has been received for this specific study. Data have been generated as part of routine work of the participating organisations. We thank Bjorn Winkens for his assistance in the statistical analyses. Declaration of personal interests: V.B.C. Biemans has no conflicts of interest to declare. C.J. van der Woude has served on advisory boards and/or received financial compensation from the following companies: MSD, FALK Benelux, Abbott laboratories, Mundipharma Pharmaceuticals, Janssen, Takeda, and Ferring during the last 3 years. A.E. van der Meulen-de Jong has served on advisory boards, or as speaker or consultant for Takeda, Tramedico, AbbVie, and has received grants from Takeda. G. Dijkstra unrestricted research grants from Abbvie, Takeda and Ferring Pharmaceuticals. Advisory boards for Mundipharma and Pharmacosmos. Received speakers fees from Takeda and Janssen Pharmaceuticals. M. Löwenberg has served as speaker and/or principal investigator for: Abbvie, Celgene, Covidien, Dr. Falk, Ferring Pharmaceuticals, Gilead, GlaxoSmithKline, Janssen-Cilag, Merck Sharp & Dohme, Pfizer, Protagonist therapeutics, Receptos, Takeda, Tillotts, Tramedico. He has received research grants from AbbVie, Merck Sharp & Dohme, Achmea healthcare and ZonMW. N.K.H. de Boer has served as a speaker for AbbVie, Takeda and MSD. He has served as consultant and principal investigator for Takeda and TEVA Pharma B.V. He has received (unrestricted) research grants from Dr. Falk and Takeda. B. Oldenburg speaker: Ferring, MSD, Abbvie. Advisory boards: Ferring, MSD, Abbvie, Takeda, Pfizer, Janssen. Research Grants: Abbvie, Ferring, Takeda, Pfizer, MSD, dr. Falk. N. Srivastava has no conflict of interest to declare. J.M. Jansen has served on advisory boards, or as speaker or consultant for Abbvie, Amgen, Ferring, Fresenius, Janssen, MSD, Pfizer, Takeda. A.G.L. Bodelier has served as speaker and/ or participant in advisory board for: Abbvie, Merck Sharp & Dohme, Takeda, Vifor Pharma, Mundipharma. R.L. West has participated in advisory board and/or received financial compensation from the following companies: Jansen and Abbvie. A.C. de Vries has participated in advisory board and/or received financial compensation from the following companies: Jansen, Takeda, Abbvie and Tramedico. D.J. de Jong Received consulting fees from Synthon, Pharma, Abbvie, and MSD, and travel fees from Falk Pharma, Takeda, Abbvie, MSD, Ferring, Vifor Pharma, and Cablon Medical. J.J.L. Haans reports personal fees from advisory board for Takeda Nederland B.V., personal fees from advisory board for Lamepro B.V., outside the submitted work. F. Hoentjen has served on advisory boards, or as speaker or consultant for Abbvie, Celgene, Janssen-Cilag, MSD, Takeda, Celltrion, Teva, Sandoz and Dr Falk, and has received unrestricted grants from Dr Falk, Janssen-Cilag, Abbvie. M.J. Pierik has served on advisory boards, or as speaker or consultant for Abbvie, Janssen-Cilag, MSD, Takeda, Ferring, Dr Falk, and Sandoz and has received unrestricted grants from, Janssen-Cilag, Abbvie and Takeda outside the submitted work. Publisher Copyright: © 2020 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd
(Peer reviewed)